ClinicalTrials.gg
CompletedNCT01045707BOOST™Updated Dec 8, 2016Results posted

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes

A Phase 3 interventional study of insulin degludec/insulin aspart and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 92 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-08.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
15th of 70
530 · median 384
Started
2010
with 11 others
Phase 3
49 of 70
2 open now
Registered
7th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 12 that started in 2010, is one of 49 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both as add-on to subject's ongoing treatment with metformin + at least one OAD (oral anti-diabetic drug).

The main period is registered internally at Novo Nordisk as NN5401-3590 while the extension period is registered as NN5401-3726.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 530 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For MAIN period (NN5401-3590):
  • Diagnosis of type 2 diabetes mellitus for at least 6 months
  • Insulin naïve subjects
  • Treatment with metformin and at least one other oral antidiabetic drug for at least 3 months before trial start
  • Glycosylated () between 7.5 - 11.0% (both inclusive)
  • (BMI) no higher than 40.0 kg/m\^2
  • For EXTENSION period (NN5401-3726):
  • obtained before any trial-related activities
  • Must have completed the 26-week treatment period (visit 28) in trial NN5401-3590

Exclusion criteria

Exclusion Criteria:

  • For MAIN period (NN5401-3590):
  • Treatment with glucagon like peptide-1 (GLP-1) receptor agonists and/or thiazolidinedione(s) within the last 3 months prior to trial start
  • Cardiovascular disease diagnosed within 6 months before trial start
  • For EXTENSION period (NN5401-3726):
  • Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic , beta-blockers, Monoamine oxidase (MAO) inhibitors
  • Anticipated significant lifestyle changes during the trial, e.g. shift work (including permanent night/evening shift workers), as well as highly variable eating habits as judged by the physician)
  • Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate measures according to local requirements
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
530 participants (actual)

Study arms

  • Experimental
    IDegAsp OD

    Drug: insulin degludec/insulin aspart

  • Experimental
    IGlar OD

    Drug: insulin glargine

Interventions

07

What researchers measure

Primary outcomes

  1. Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: Week 0, Week 26

  2. Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes

    Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Week 0 to Week 53 + 7 days follow up

  3. Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes

    Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

    Time frame: Week 0 to Week 53 + 7 days follow up

  4. Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)

    Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild:no or transient symptoms, no interference with the subject's daily activities. Moderate: marked symptoms, moderate interference with the subject's daily activities. Severe: considerable interference with the subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalisation/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect

    Time frame: Week 0 to Week 53 + 7 days follow up

Secondary outcomes

  1. Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment

    Change from baseline in HbA1c after 52 weeks of treatment.

    Time frame: Week 0, Week 53

  2. Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26

    Mean of SMPG at 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.

    Time frame: Week 26

08

Results

Posted Nov 20, 2015

Participant flow

The trial was conducted at 88 sites in 8 countries: Austria (4), India (7), South Korea (5), Poland (6), Russia (10), Spain (11), Turkey (5), and United States of America (40). Some sites did not enroll subjects in the extension period.

Main: Week 0 to 26 (NN5401-3590)
Participant flow — Main: Week 0 to 26 (NN5401-3590)
MilestoneIDegAsp ODIGlar OD
Started266264
Exposed265261
Completed219232
Not completed4732
Withdrew: Adverse event53
Withdrew: Lack of efficacy42
Withdrew: Protocol violation65
Withdrew: Withdrawal criteria2211
Withdrew: Unclassified1011
Extension: Week 27 to 52 (NN5401-3726)
Participant flow — Extension: Week 27 to 52 (NN5401-3726)
MilestoneIDegAsp ODIGlar OD
Started192221
Completed179209
Not completed1312
Withdrew: Adverse event33
Withdrew: Protocol violation23
Withdrew: Withdrawal criteria21
Withdrew: Unclassified65

Outcome measures

PrimaryMain Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment

Change from baseline in HbA1c after 26 weeks of treatment.

Time frame:
Week 0, Week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
percentage of glycosylated haemoglobinIDegAsp ODIGlar OD
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment-1.65 ± 1.28-1.72 ± 1.17
SecondaryExtension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment

Change from baseline in HbA1c after 52 weeks of treatment.

Time frame:
Week 0, Week 53
Reported as:
Mean · percentage of glycosylated haemoglobin
Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
percentage of glycosylated haemoglobinIDegAsp ODIGlar OD
Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment-1.39 ± 1.23-1.34 ± 1.16
SecondaryMain Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26

Mean of SMPG at 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.

Time frame:
Week 26
Reported as:
Mean · mmol/L
Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26
mmol/LIDegAsp ODIGlar OD
Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 267.9 ± 2.17.9 ± 1.7
PrimaryExtension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes

Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Week 0 to Week 53 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDegAsp ODIGlar OD
Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes419211
PrimaryExtension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes

Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

Time frame:
Week 0 to Week 53 + 7 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDegAsp ODIGlar OD
Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes1953
PrimaryExtension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)

Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild:no or transient symptoms, no interference with the subject's daily activities. Moderate: marked symptoms, moderate interference with the subject's daily activities. Severe: considerable interference with the subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalisation/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect

Time frame:
Week 0 to Week 53 + 7 days follow up
Reported as:
Number · Events/100 years of patient exposure
Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)
Events/100 years of patient exposureIDegAsp ODIGlar OD
Adverse events (AE)313238
Serious AE179
Severe AE910
Moderate AE7766
Mild AE227162
Fatal AE21

Adverse events

Collected over Week 0 to Week 53 + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegAsp OD—30/265 (11.3%)88/265 (33.2%)
IGlar OD—15/261 (5.7%)79/261 (30.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventIDegAsp ODIGlar OD
Acute myocardial infarctionCardiac disorders2/2650/261
Hypoglycaemic unconsciousnessMetabolism and nutrition disorders2/2651/261
Duodenal Ulcer HaemorrhageGastrointestinal disorders2/2650/261
Myocardial infarctionCardiac disorders2/2650/261
Ileus paralyticGastrointestinal disorders0/2651/261
Bile duct stoneHepatobiliary disorders0/2651/261
CholelithiasisHepatobiliary disorders1/2651/261
Skull fractureInjury, poisoning and procedural complications0/2651/261
Renal colicRenal and urinary disorders0/2651/261
Respiratory distressRespiratory, thoracic and mediastinal disorders0/2651/261
Most frequent other events
Most frequent other events
EventIDegAsp ODIGlar OD
NasopharyngitisInfections and infestations36/26535/261
HypertensionVascular disorders20/26511/261
HeadacheNervous system disorders16/26511/261
Back PainMusculoskeletal and connective tissue disorders16/26511/261
DiarrhoeaGastrointestinal disorders13/26515/261
Upper Respiratory Tract InfectionInfections and infestations15/26512/261
BronchitisInfections and infestations14/26510/261

Baseline characteristics

Baseline characteristics for all the randomised subjects (the full analysis set \[FAS\]) were collected at the beginning of main trial. One subject was excluded from FAS because the subject was randomised in error and was not dosed.

Age, Continuous
Age, Continuous(years)IDegAsp ODIGlar ODTotal
Mean57.4 ± 9.056.4 ± 9.256.9 ± 9.1
Gender
Gender(Participants)IDegAsp ODIGlar ODTotal
Female141127268
Male125136261
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegAsp ODIGlar ODTotal
Mean8.9 ± 1.08.9 ± 0.98.9 ± 0.9
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDegAsp ODIGlar ODTotal
Mean10.1 ± 2.910.4 ± 2.810.2 ± 2.9
09

Study locations

92 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35233, United States
  • Novo Nordisk Investigational Site
    Vestavia, Alabama 35209, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520-1926, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Waterbury, Connecticut 06708, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33135, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33136, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33169, United States
  • Novo Nordisk Investigational Site
    North Miami, Florida 33161, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96813, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Council Bluffs, Iowa 51501, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70006-2930, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70119, United States
  • Novo Nordisk Investigational Site
    Detroit, Michigan 48235, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48085-5524, United States
  • Novo Nordisk Investigational Site
    Springfield, Missouri 65807, United States
  • Novo Nordisk Investigational Site
    St. Charles, Missouri 63303, United States
  • Novo Nordisk Investigational Site
    Brooklyn, New York 11203, United States
  • Novo Nordisk Investigational Site
    Smithtown, New York 11787, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557, United States
  • Novo Nordisk Investigational Site
    Wilson, North Carolina 27893, United States
  • Novo Nordisk Investigational Site
    Tulsa, Oklahoma 74104, United States
  • Novo Nordisk Investigational Site
    Portland, Oregon 97220, United States
  • Novo Nordisk Investigational Site
    Portland, Oregon 97239, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38119, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75235, United States
  • Novo Nordisk Investigational Site
    Lubbock, Texas 79423, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78240, United States
  • Novo Nordisk Investigational Site
    Tomball, Texas 77375, United States
  • Novo Nordisk Investigational Site
    St. George, Utah 84790, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Olympia, Washington 98502, United States
  • Novo Nordisk Investigational Site
    Ebreichsdorf, 2483, Austria
  • Novo Nordisk Investigational Site
    Feldbach, 8330, Austria
  • Novo Nordisk Investigational Site
    Innsbruck, 6020, Austria
  • Novo Nordisk Investigational Site
    Salzburg, 5010, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, 1060, Austria
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400053, India
  • Novo Nordisk Investigational Site
    Jaipur, Rajasthan 302006, India
  • Novo Nordisk Investigational Site
    Trichy, Tamil Nadu 620018, India
  • Novo Nordisk Investigational Site
    Bangalore, 560038, India
  • Novo Nordisk Investigational Site
    Kerala, 682026, India
  • Novo Nordisk Investigational Site
    Patna, 800020, India
  • Novo Nordisk Investigational Site
    Pucheon, 424-017, Korea, Republic of
  • Novo Nordisk Investigational Site
    Pusan, 602-739, Korea, Republic of
  • Novo Nordisk Investigational Site
    Seoul, 08308, Korea, Republic of
  • Novo Nordisk Investigational Site
    Seoul, 137-701, Korea, Republic of
  • Novo Nordisk Investigational Site
    Seoul, 158-710, Korea, Republic of
  • Novo Nordisk Investigational Site
    Krakow, 31-261, Poland
  • Novo Nordisk Investigational Site
    Lodz, 90-003, Poland
  • Novo Nordisk Investigational Site
    Lodz, 93-338, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-044, Poland
  • Novo Nordisk Investigational Site
    Pruszkow, 05-800, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 02-507, Poland
  • Novo Nordisk Investigational Site
    Bayamon, 00961, Puerto Rico
  • Novo Nordisk Investigational Site
    Arkhangelsk, 163045, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Nizhniy Novgorod, 603126, Russian Federation
  • Novo Nordisk Investigational Site
    Orenburg, 460040, Russian Federation
  • Novo Nordisk Investigational Site
    Samara, 443067, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410053, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410710, Russian Federation
  • Novo Nordisk Investigational Site
    Smolensk, 214019, Russian Federation
  • Novo Nordisk Investigational Site
    Stavropol, 355017, Russian Federation
  • Novo Nordisk Investigational Site
    Yaroslavl, 150003, Russian Federation
  • Novo Nordisk Investigational Site
    Barcelona, 08035, Spain
  • Novo Nordisk Investigational Site
    Málaga, 29006, Spain
  • Novo Nordisk Investigational Site
    Mérida, 06800, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07198, Spain
  • Novo Nordisk Investigational Site
    Partida de Bacarot, 03114, Spain
  • Novo Nordisk Investigational Site
    Pozuelo de Alarcon, 28223, Spain
  • Novo Nordisk Investigational Site
    San Sebastián de los Reyes, 28700, Spain
  • Novo Nordisk Investigational Site
    Santiago de Compostela, 15706, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41009, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46014, Spain
  • Novo Nordisk Investigational Site
    Valladolid, 47005, Spain
  • Novo Nordisk Investigational Site
    Antalya, 07058, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34096, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34390, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34400, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34760, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, Turkey
10

References and documents

Publications

  • Kumar A, Franek E, Wise J, Niemeyer M, Mersebach H, Simo R. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naive Patients with Type 2 Diabetes: A Randomized Controlled Trial. PLoS One. 2016 Oct 19;11(10):e0163350. doi: 10.1371/journal.pone.0163350. eCollection 2016. PubMed 27760129 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 5 years 1 month after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2010
First posted
Jan 11, 2010
Start
Jan 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results delay requested
Feb 24, 2011
Results first posted
Nov 20, 2015
Last update
Dec 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01045707
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 11, 2010
Start date
Jan 2010
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Nov 20, 2015
Last update
Dec 8, 2016

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart · Insulin Glargine

Start the discussion